GPCR-β-arrestin interactions are an emerging field in GPCR drug discovery. Accurate, precise and easy to set up methods are necessary to monitor such interactions in living systems. We show a structural complementation assay to monitor GPCR-β-arrestin interactions in real time living cells, and it can be extended to any GPCR.
Cite this ArticleCopy Citation | Download Citations | Reprints and Permissions
Reyes-Alcaraz, A., Lee, Y. N., Yun, S., Hwang, J. I., Seong, J. Y. Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery. J. Vis. Exp. (148), e59994, doi:10.3791/59994 (2019).
Translate text to:
Interactions between G-protein coupled receptors (GPCRs) and β-arrestins are vital processes with physiological implications of great importance. Currently, the characterization of novel drugs towards their interactions with β-arrestins and other cytosolic proteins is extremely valuable in the field of GPCR drug discovery particularly during the study of GPCR biased agonism. Here, we show the application of a novel structural complementation assay to accurately monitor receptor-β-arrestin interactions in real time living systems. This method is simple, accurate and can be easily extended to any GPCR of interest and also it has the advantage that it overcomes unspecific interactions due to the presence of a low expression promoter present in each vector system. This structural complementation assay provides key features that allow an accurate and precise monitoring of receptor-β-arrestin interactions, making it suitable in the study of biased agonism of any GPCR system as well as GPCR c-terminus ‘phosphorylation codes’ written by different GPCR-kinases (GRKs) and post-translational modifications of arrestins that stabilize or destabilize the receptor-β-arrestin complex.
GPCRs represent the target of nearly 35% of current drugs in the market1,2 and a clear understanding of their pharmacology is crucial in the development of novel therapeutic drugs3. One of the key aspects in GPCR drug discovery, particularly during the development of biased agonists is the characterization of novel ligands towards receptor-β-arrestin interactions4 and β-arrestin interactions with other cytosolic proteins such as clathrin5.
It has been documented that β-arrestin dependent signaling plays a key role in neurological disorders such as bipolar disorder, major depression, and schizophrenia6 and also severe side effects in some medications such as morphine7.
Current methods used to monitor these interactions usually do not represent actual endogenous levels of the proteins in study, in some cases they show weak signal, photobleaching and depending of the GPCR it might be technically challenging to set up8. This novel structural complementation assay uses low expression promoter vectors in order to mimic endogenous physiological levels and provides high sensitivity compared to current methods9. Using this approach, it was possible to easily characterize Galanin receptor-β-arrestin1/2 and also β-arrestin2-clathrin interactions10. This methodology can be widely used to any GPCR of particular interest where β-arrestins play a key physiological function or their signaling is relevant in some diseases.
1. Primer design strategy
- Design primers to introduce genes of interest into pBiT1.1-C [TK/LgBiT], pBiT2.1-C [TK/SmBiT], pBiT1.1-N [TK/LgBiT] and pBiT2.1-N [TK/SmBiT] Vectors.
- Select at least one of these three sites as one of the two unique restriction enzymes needed for directional cloning due to the presence of an in-frame stop codon that divides the multicloning site as shown in Figure 111.
- Incorporate nucleotide sequence into the primers as shown in Table 1 to encode the linker residues shown in red in Table 211.
- For pBiT1.1-C [TK/LgBiT] and pBiT2.1-C [TK/SmBiT] vectors, make sure that the 5 ́ primer contains an ATG codon and a potent Kozak consensus sequence (GCCGCCACC).
- For pBiT1.1-N [TK/LgBiT] and pBiT2.1-N [TK/SmBiT] vectors, ensure that the 3 ́ primer contains a stop codon.
NOTE: Each vector contains the HSV-TK promoter to minimize nonspecific association and reduce experimental artifacts, also each vector has an expression cassette for ampicillin resistance in bacteria.
- Set up and run PCR reactions to amplify the insert DNA of the gene of interest using the primers designed from step 1. It is important to use a high-fidelity DNA polymerase to minimize mutations.
- Use exactly the following order to prepare 50 µL of PCR reaction. Add 35.5 µL of distilled water, 5 µL of 10x Polymerase buffer, 5 µL of dNTP mixture (2.5 mM each), 1 µL of plasmid template (200 ng/µL), 1.25 µL of forward and reverse primers (10 μM) and 1 µL of high-fidelity polymerase (5 U/µL).
- Using a thermocycler set up the following DNA amplification program.
- Denature at 95 °C for 5 min.
- Repeat 25 times the following thermal cycle: 95 °C for 30 s, 60 °C for 1 min, 72 °C for 2 min per 1 kbp to be amplified.
- Run a final extension at 72 °C for 10 min.
- Hold the samples at 4 °C within the thermocycler.
NOTE: It is highly recommended to use a high-fidelity polymerase in order to minimize point mutations particularly those occurring during the amplification of long sequences. As the amplicon becomes longer, the degree of accuracy in the replication of the DNA decreases. For the PCR reaction, choose the annealing temperature based on the melting temperature of the region where the oligos directly hybridize with the DNA template and not with all the sequence of the primer.
- PCR product purification
- Isolate the PCR product from the rest of the PCR reaction using a kit from a manufacturer of preference12. The PCR product is now ready for restriction digestion.
3. DNA digestion
- For the PCR product digestion prepare 50 μL of digestion reaction as follows.
- Using a 1.5 mL tube, add 12 μL of distilled water.
- Add 5 μL of 10x buffer with the best compatibility with both restriction enzymes.
- From step 2.4 add 30 μL of PCR product
- Finally, add 1.5 μL of each restriction enzyme.
- Briefly mix by vortex and incubate at 37.5 °C overnight.
- For the recipient plasmid digestion prepare 50 μL of digestion reaction as follows:
- Using a 1.5 mL tube, add 23 μL of distilled water.
- Add 5 μL of 10x buffer with the best compatibility with both restriction enzymes.
- Add 15 μL of recipient plasmid (200 ng/μL).
- Add 1.5 μL of each restriction enzyme.
- Briefly mix by vortex and incubate at 37.5 °C overnight.
NOTE: It is important to use 3 μg of recipient plasmid in order to obtain sufficient material after DNA agarose gel purification. It is also relevant to leave DNA digestions overnight using both enzymes to obtain high cloning efficiency.
4. DNA agarose gel purification and cloning
- Prepare a 1% agarose gel to run the digested DNA plasmid and inserts and proceed to cut the corresponding bands. Once the corresponding vector and insert bands have been purified12, determine the DNA concentration using a spectrophotometer.
- Perform DNA ligation to fuse the insert to the recipient plasmid.
- Prepare ligation reactions of around 100 ng of total DNA including 50 ng of plasmid vector.
- Set up recipient plasmid-insert ratio of approximately 1:3; it can be calculated using a vector-insert calculator13.
- Set up negative controls in parallel. For instance, a ligation of the recipient plasmid DNA without any insert will provide information about how much background of undigested or self-ligating recipient plasmid is present.
5. Transformation of clones
- Place a tube of DH5α competent cells from the freezer at -80 °C and immediately transfer it on ice for 20 min.
- After that time, take 55 µL of DH5α competent cells and add 4 µL of ligation reaction and mix by flicking the tube and store on ice for 45 min.
- Place the tube in a water bath previously warmed at 42 °C for exactly 48 s and immediately get the tubes back on ice for another 3 min.
- Add 600 µL of Luria Broth (LB) medium previously warmed at 37.5 °C and incubate with shaking for 1 hour at 200 rpm.
- Transfer 200 µL into an agar plate containing ampicillin 100 μg/mL and gently spread over the surface with the liquid is mostly absorbed.
- Incubate the plates overnight to see the colonies next morning. The recipient plasmid on the insert plate should have significantly more colonies than the recipient plasmid alone plate.
6. Isolation of the finished plasmid
- Pick 3-10 individual bacterial colonies and transfer into 1 mL of LB medium containing ampicillin (100 μg/mL) and incubate for 6 h.
- Take 200 µL of bacterial suspension and transfer to 5 mL of LB medium containing the same concentration of ampicillin as in step 6.1 and incubate overnight at 37.5 °C with shaking at 200 rpm.
- Using a miniprep DNA kit purification, perform miniprep DNA purifications using 5 mL of LB grown overnight following the manufacturer instructions14.
- To identify successful ligations, set up PCR reactions in the same way as in section 2 using the DNA obtained from step 6.3 as a template with the same primers as in section 2 during the first PCR. Positive clones will produce PCR products with the corresponding size.
- After large prep DNA purification of the positive clones, conduct a diagnostic restriction digestion of 500 ng of purified DNA with the enzymes used during the cloning step and run the digested products on an 1% agarose gel. There should be two bands: one the size of the vector and one the size of the new insert.
- Verify the construct sequence by sequencing using the following primers: Forward 5’- aaggtgacgcgtgtggcctcgaac-3’ and reverse 5’-gcatttttttcactgcattctagtt-3’.
NOTE: When DNA is replicated using PCR, there is always the possibility of errors during the amplification even when using a high-fidelity polymerase, therefore is very important to sequence the final constructs.
7. Transfection and protein expression
- In a previously poly-L-lysine-coated white 96 well plate, perform cell seeding one day before transfection at 2.5 x 104 cells per well using Dulbecco’s modified Eagle’s medium supplemented with 10% of Fetal Bovine Serum, 100 U/mL penicillin G, and 100 μg/mL streptomycin.
- Use only the 60 inner wells to minimize the potential for thermal gradients across the plate and edge effects from evaporation. Add 200 μL of sterile distilled water to the 36 outside wells and 150 μL in the spaces between wells and incubate overnight at 37.5 °C and 5% of CO2.
- The following morning perform transfection using 100 ng of total DNA (50 ng each construct).
- Set up four different plasmid combinations (receptor:β-arrestin) according to Figure 2b.
- For each plasmid combination use 20 µL of modified Eagle's Minimum Essential Media buffered with HEPES using 0.3 µL of lipidic transfection reagent per well.
- Add 20 μL of lipidic transfection reagent-DNA mixture to each well and mix the plate in circles for 10 s.
- Change fresh medium after 6 hr incubation at 37.5 °C and 5% CO2.
- Incubate the plate for 24 h at 37.5 °C and 5% CO2.
8. Monitoring receptor-β-arrestin1/2 interactions in HEK293 cells
- Aspirate medium and add 100 μL of modified Eagle's Minimum Essential Media buffered with HEPES to each well and let the plate stabilize at RT for 10 min.
- Prepare the furimazine substrate by combining 1 volume of 100x substrate with 19 volumes of LCS Dilution Buffer (a 20-fold dilution)11, creating a 5x stock to mix with cell culture medium.
- Add 25 μL of 5x furimazine to each well and gently mix in circles for 10 s.
- Measure luminescence for 10 min for signal stabilization at RT.
NOTE: By using this baseline signal to normalize the response of each well it will help to reduce variability caused by differences in the number of cells plated per well, also differences in transfection efficiency, etc. Once calculated, average the normalized response from replicate wells for a given drug treatment.
- Prepare 13.5x ligand solution in modified Eagle's Minimum Essential Media buffered with HEPES.
- For experiments at room temperature with 10 µL of 13.5x ligand addition, add the compounds using injectors or a multichannel pipette and mix the plate by hand or using an orbital shaker (20 s at 200 rpm).
- For experiments at 37.5 °C with 10 µL of 13.5x ligand addition, use injectors to dispense compounds and mix by using the instrument orbital shaker. In case of not using injectors, remove the plate from the luminometer, add the ligands and mix the plate by hand or using an orbital shaker (20 s at 200 rpm).
NOTE: Use injectors and a shaker within the detection instrument to minimize temperature fluctuations associated with removing the plate from the luminometer. Standard benchtop luminometers can be used for this assay. Use an integration time of 0.25–2 s.
Using the procedure presented here, interactions between a prototypical GPCR and two β-arrestin isoforms were monitored. Glucagon like peptide receptor (GLP-1r) constructs were made using primers containing NheI and EcoRI enzyme restriction sites and cloned into the vectors pBiT1.1-C [TK/LgBiT] and pBiT2.1-C [TK/SmBiT] while in the case of β-arrestins, two additional vectors were used pBiT1.1-N [TK/LgBiT] and pBiT2.1-N [TK/SmBiT] using enzyme restriction sites BgIII and EcoRI in the case of β-arrestin2 and NheI and XhoI in the case of β-arrestin1. HEK293 cells were transfected using 50 ng of GLP-1r-LgBiT/SmBiT and 50 ng of β-arrestin tagged with LgBiT or SmBiT at the N- or C-terminal. Four different plasmid combinations were screened (Figure 3) and the one with the highest luminescent signal was chosen for further experiments (Figure 4). In order to determine the EC50 values for each β-arrestin isoform recruitment, dose response curves were performed using 10 μM, 1 μM, 100 nM, 10 nM and 1 nM of GLP-1 ligand concentration (Figure 4c). Dose response curves were obtained from the maximum response of each concentration from the kinetic studies (Figure 4a, 4b).
Figure 1. Nucleotide sequences of the multicloning sites of the vectors used in the design of GLP-1r-β-arrestin1/2 structural complementation assay.
In order to develop the structural complementation assay for GLP-1r-β-arrestin1/2 system, it was necessary to tag at the C-terminal the GLP-1r with LgBiT and SmBiT using the enzyme restrictions NheI and EcoRI at the pBiT1.1-C [TK/LgBiT] and pBiT2.1-C [TK/SmBiT] vector. In the case of β-arrestin1/2 they also were tagged with the LgBiT and SmBiT at the C- and N-terminal using the enzyme restrictions BglII/EcoRI for β-arrestin2 and NheI/XhoI for β-arrestin1 at the four vectors. All vectors use the HSV-TK promoter to minimize nonspecific association and reduce experimental artifacts and each vector contains an expression cassette for ampicillin resistance in bacteria. Image adapted from reference 11. Please click here to view a larger version of this figure.
Figure 2. Schematic representation of the GPCR:β-arrestin1/2 structural complementation assay.
(a) How the GPCR:β-arrestin1/2 structural complementation assay works in the presence of ligand. (b) Structural representation of the different plasmid combinations for the GPCR and β-arrestin isoforms tagged with LgBiT or SmBiT. Please click here to view a larger version of this figure.
Figure 3. GLP-1r/β-arrestins orientation screening.
In order to obtain the highest sensitivity 4 different plasmid combinations were expressed during 24 h after transfection. Luminescent signals were detected in almost all different plasmid combinations (a-c) except for only one GLP-1r:β-arrestin orientation (d). The results are expressed as mean ± S.E.M. of two experiments performed in duplicate; each duplicate was averaged before calculating the S.E.M. The arrows indicate the time at which the cells were treated with GLP-1 at 10 μM final concentration. Please click here to view a larger version of this figure.
Figure 4. GLP-1r-β-arrestin1/2 interactions are dose dependent manner.
Dose dependent ligand relationship of β-arrestin2 (a) and β-arrestin1 recruitment (b). Dose response curves showing differential recruitment between β-arrestin1 and β-arrestin2 by GLP-1r (c). The results are expressed as mean ± S.E.M. of two experiments performed in duplicate; each duplicate was averaged before calculating the S.E.M. The arrows indicate the time at which the cells were treated with GLP-1 at the corresponding concentrations (10 μM, 1 μM, 100 nM, 10 nM and 1 nM, final concentrations). Please click here to view a larger version of this figure.
|Vector||Enzyme restriction used||Primer sequence|
|pBiT1.1-C [TK/LgBiT] / pBiT2.1-C [TK/SmBiT]||SacI||5 ́-XXXXXXXXGAGCTCC(Rev SI)-3 ́|
|EcoRI||5 ́-XXXXXXXXGAATTCCC(Rev SI)-3 ́|
|XhoI||5 ́-XXXXXXXXCTCGAGCC(Rev SI)-3 ́|
|pBiT1.1-N [TK/LgBiT] / pBiT2.1-N [TK/SmBiT]||Xho||5 ́-XXXXXXXXCTCGAGCGGT (SI)-3 ́|
|SacI||5 ́-XXXXXXXXGAGCTCAG(SI)-3 ́|
|EcoRI||5 ́-XXXXXXXXGAATTCA(SI)-3 ́|
Table 1. Sequences of primers for the different restriction enzyme sites in the coding sequence of the linker for the pBiT1.1 and pBiT2.1 Vectors.
SI = Sequence of interest; Rev SI = reverse complementary of the sequence of interest. Table adapted from reference 11.
|Vector||Linker sequence||Enzyme restriction used|
|pBiT1.1-C [TK/LgBiT] / pBiT2.1-C [TK/SmBiT]||SI-GlyAlaGlnGlyAsnSerGlySerSerGlyGlyGlyGlySerGlyGlyGlyGlySerSerGly-(LgBiT/SmBiT)||SacI|
|pBiT1.1-N [TK/LgBiT] / pBiT2.1-N [TK/SmBiT]||(LgBiT/SmBiT)-GlySerSerGlyGlyGlyGlySerGlyGlyGlyGlySerSerGly-SI||XhoI|
Table 2. Linker amino acid sequences related with SacI, EcoRI or XhoI restriction sites in the pBiT1.1 and pBiT2.1 Vectors.
Red residues have to be encoded by PCR primers. Table adapted from reference 11.
Using the method presented here, interactions between any GPCR and β-arrestin1/2 can be monitored in real time living systems using this GPCR-β-arrestin structural complementation assay. In this regard, we were able to observe differential β-arrestin recruitment between the two β-arrestin isoforms by the GLP-1r (A prototypical Class B GPCR), we also observed a dissociation of the receptor-β-arrestin complex a few minutes after reaching the maximum luminescent signal.
In order to have the best sensitivity in the structural complementation assay system, it was screened with four different spatial orientations between the receptor and each β-arrestin isoform and the one with highest luminescent signal was used for posterior studies such as dose response stimulation curves (Figure 4). Using this methodology it was possible to characterize receptor-β-arrestin interactions using a GPCR of high therapeutic value in endocrinological diseases such as Diabetes mellitus15. In the same way this strategy can be easily adapted to any GPCR by simple tagging the GPCR of interest with LgBiT or SmBiT at the C-terminal and using the β-arrestin1/2 constructs described here and it emerges as a powerful alternative to current methodologies without the necessity of a complex set up where the overlapping between the donor and acceptor can be an obstacle as in some cases of BRET and FRET. Another significant advantage is that the vectors used in this system contain low expression promoters in an attempt to mimic endogenous expression levels. With this feature, we can rule out the possibility of non-specific associations due to high expression levels of the receptor and/or β-arrestin. In Figure 3 and Figure 4, there is a clear difference in the receptor-β-arrestin complex between β-arrestin1 versus β-arrestin2 and also a higher efficacy and intensity towards β-arrestin1 over β-arrestin2. The screening into four different orientations was proposed to increase the sensitivity of the assay making the system highly sensitive even at endogenous expression levels.
This methodology is very straight forward to perform. Perhaps the most critical step within this protocol is the primer design to amplify the receptor of interest. The user must be very careful in selecting what restriction enzyme to use according to Figure 1 and based on this to add the corresponding nucleotides to the primers (Table 1) to encode the red highlighted amino acids (Table 2).
One limitation of this methodology can be that the furimazine will degrade in an aqueous solution at or near physiological pH, leading to a gradual decrease in luminescence intensity independent of any change in GPCR-β-arrestin interactions16. To overcome this limitation the user should always include a normalization control (vehicle treated samples) when continuously monitoring luminescence for extended time periods. It is also important to use low levels of fetal bovine serum during the assay since its presence it might increase the rate of furimazine degradation16. One problem that may arise during the assay is that for luminescent values for a known GPCR-β-arrestin interaction can be no significant increase is registered compared to the base line values in all four different plasmid combinations. This can be due to the low expression from the HSV-TK promoter17. In that case, one alternative is to subclone the Open Reading Frames encoding LgBiT and SmBiT fusion proteins into expression vectors using the CMV promoter. When changing to a stronger promoter, optimization of the amount of transfected DNA should be done in order to obtain the best assay response.
Using this structural complementation assay we were able to observe with great accuracy the β-arrestin1/2 recruitment interactions by a prototypical class B GPCR. Using this method, it is possible to pharmacologically characterize novel drugs of particular interest targeting GPCRs.
The authors declare no competing interests.
This work was supported by grants from the Research Program (NRF- 2015M3A9E7029172) of the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning.
|Antibiotics penicillin streptomycin||Welgene||LS202-02||Penicillin/Streptomycin|
|Bacterial Incubator||JEIO Tech||IB-05G||Incubator (Air-Jacket), Basic|
|Cell culture medium||Welgene||LM 001-05||DMEM Cell culture medium|
|Cell culture transfection medium||Gibco||31985-070||Optimem 1X cell culture medium|
|CO2 Incubator||NUAIRE||NU5720||Direct Heat CO2 Incubator|
|Digital water bath||Lab Tech||LWB-122D||Digital water bath lab tech|
|DNA Polymerase proof reading||ELPIS Biotech||EBT-1011||PfU DNA polymerase|
|DNA purification kit||Cosmogenetech||CMP0112||miniprepLaboPass Purificartion Kit Plasmid Mini|
|DNA Taq Polymerase||Enzynomics||P750||nTaq DNA polymerase|
|Enzyme restriction BglII||New England Biolabs||R0144L||BglII|
|Enzyme restriction buffer||New England Biolabs||B72045||CutSmart 10X Buffer|
|Enzyme restriction EcoRI||New England Biolabs||R3101L||EcoRI-HF|
|Enzyme restriction NheI||New England Biolabs||R01315||NheI|
|Enzyme restriction XhoI||New England Biolabs||R0146L||XhoI|
|Fetal Bovine Serum||Gibco Canada||12483020||Fetal Bovine Serum|
|Gel/PCR DNA MiniKit||Real Biotech Corporation||KH23108||HiYield Gel/PCR DNA MiniKit|
|Ligase||ELPIS Biotech||EBT-1025||T4 DNA Ligase|
|Light microscope||Olympus||CKX53SF||CKX53 Microscope Olympus|
|lipid transfection reagent||Invitrogen||11668-019||Lipofectamine 2000|
|Luminometer||Biotek/Fisher Scientific||12504386||Synergy 2 Multi-Mode Microplate Readers|
|NanoBiT System||Promega||N2014||NanoBiT PPI MCS Starter System|
|Nanoluciferase substrate||Promega||N2012||Nano-Glo Live Cell assay system|
|PCR Thermal cycler||Eppendorf||6336000015||Master cycler Nexus SX1|
|Poly-L-lysine||Sigma Aldrich||P4707-50ML||Poly-L-lysine solution|
|Trypsin EDTA||Gibco||25200-056||Trysin EDTA 10X|
|White Cell culture 96 well plates||Corning||3917||Assay Plate 96 well plate|
- Sriram, K., Insel, P. A. GPCRs as targets for approved drugs: How many targets and how many drugs? Molecular Pharmacology. 93, (4), 251-258 (2018).
- Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery. 16, (12), 829-842 (2017).
- Langmead, C. J., Summers, R. J. Molecular pharmacology of GPCRs. British Journal of Pharmacology. 175, (21), 1754005-1754008 (2018).
- Lohse, M. J., Hoffmann, C. Arrestin Interactions with G Protein-Coupled Receptors. Handbook of Experimental Pharmacology. 219, 15-56 (2014).
- Kang, D. S., et al. Structure of an arrestin2-clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking. Journal of Biological Chemistry. 284, 29860-29872 (2009).
- Park, S. M., et al. Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice. Neuropsychopharmacology. 41, (3), 704-715 (2016).
- Zhu, L., Cui, Z., Zhu, Q., Zha, X., Xu, Y. Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects. Mini-Reviews in Medicinal Chemistry. 18, (19), 1603-1610 (2018).
- Smith, J. S., Lefkowitz, R. J., Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nature Reviews Drug Discovery. 17, (4), 243-260 (2018).
- Dixon, A. S. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chemical Biology. 11, (2), 400-408 (2016).
- Reyes-Alcaraz, A., Lee, Y. N., Yun, S., Hwang, J. I., Seong, J. Y. Conformational signatures in β-arrestin2 reveal natural biased agonism at a G-protein-coupled receptor. Communications Biology. 3, 1-128 (2018).
- Promega. Nanobit Protein Protein Interaction System Protocol. https://www.promega.com/-/media/files/resources/protocols/technical-manuals/101/nanobit-protein-protein-interaction-system-protocol.pdf?la=en (2019).
- Life Biomedical. HiYield Gel/PCR Fragments Extraction Kit. https://www.lifebiomedical.com/uploads/2/4/7/2/24727678/gel_pcr_dna_fragments_extraction_kitydf_protocol_v3.0.pdf (2019).
- New England BioLabs. Ligation Calculator. https://nebiocalculator.neb.com/#!/ligation (2019).
- Cosmo Genetech. http://www.cosmogenetech.com/cosmo/productmngr/prm11.jsp?P_BR_CD=1&P_CTG_CD=1&P_PRODUCT_CD=1&P_N_PAGE=1&P_CAT_POS= (2019).
- Baggio, L. L., Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132, 2131-2157 (2007).
- ProMega. NanoGLO Endurazine and Vivazine Live Cell Substrates Technical Manual. https://www.promega.com/-/media/files/resources/protocols/technical-manuals/500/nano-glo-endurazine-and-vivazine-live-cell-substrates-technical-manual.pdf?la=en (2019).
- Ali, R., Ramadurai, S., Barry, F., Nasheuer, H. P. Optimizing fluorescent protein expression for quantitative fluorescence microscopy and spectroscopy using herpes simplex thymidine kinase promoter sequences. FEBS Open Bio. 8, (6), 1043-1060 (2018).